Dova Pharmaceuticals Stock Price, Forecast & Analysis (NASDAQ:DOVA)

Dova Pharmaceuticals trades on the NASDAQ under the ticker symbol "DOVA."

Dova Pharmaceuticals Inc (NASDAQ:DOVA) released its earnings results on Tuesday, August, 6th. The company reported ($0.60) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.57) by $0.03. The business had revenue of $3.52 million for the quarter, compared to analysts' expectations of $5.63 million. Dova Pharmaceuticals had a negative return on equity of 101.60% and a negative net margin of 544.09%. View Dova Pharmaceuticals' Earnings History.

6 Wall Street analysts have issued 1 year price targets for Dova Pharmaceuticals' stock. Their forecasts range from $15.00 to $30.00. On average, they expect Dova Pharmaceuticals' share price to reach $26.42 in the next twelve months. This suggests that the stock has a possible downside of 5.8%. View Analyst Price Targets for Dova Pharmaceuticals.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dova Pharmaceuticals in the last year. There are currently 4 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Dova Pharmaceuticals.

Media stories about DOVA stock have trended somewhat positive this week, InfoTrie Sentiment reports. The research firm identifies positive and negative media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Dova Pharmaceuticals earned a media sentiment score of 1.8 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Dova Pharmaceuticals.

Dova Pharmaceuticals saw a decrease in short interest in the month of October. As of October 31st, there was short interest totalling 572,700 shares, a decrease of 51.9% from the September 30th total of 1,190,000 shares. Based on an average trading volume of 587,400 shares, the short-interest ratio is presently 1.0 days. Currently, 4.4% of the company's shares are short sold. View Dova Pharmaceuticals' Current Options Chain.

Some companies that are related to Dova Pharmaceuticals include Alkermes (ALKS), FibroGen (FGEN), Evotec (EVTCY), HUTCHISON CHINA/S (HCM), Taro Pharmaceutical Industries (TARO), Global Blood Therapeutics (GBT), Genmab A/S (GMAB), Emergent Biosolutions (EBS), Intercept Pharmaceuticals (ICPT), PTC Therapeutics (PTCT), Biohaven Pharmaceutical (BHVN), Deciphera Pharmaceuticals (DCPH), Myokardia (MYOK), Amicus Therapeutics (FOLD) and Uniqure (QURE).

Based on aggregate information from My MarketBeat watchlists, some companies that other Dova Pharmaceuticals investors own include Global Blood Therapeutics (GBT), Arrowhead Pharmaceuticals (ARWR), Sasol (SSL), Aldeyra Therapeutics (ALDX), Fate Therapeutics (FATE), Heron Therapeutics (HRTX), TESARO (TSRO), TherapeuticsMD (TXMD), Viking Therapeutics (VKTX) and Allena Pharmaceuticals (ALNA).

(DOVA) raised $66 million in an initial public offering on Thursday, June 29th 2017. The company issued 4,100,000 shares at $15.00-$17.00 per share. J.P. Morgan, Jefferies and Leerink Partners served as the underwriters for the IPO.

Dova Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include GW&K Investment Management LLC (1.15%), Gabelli Funds LLC (0.26%), GABELLI & Co INVESTMENT ADVISERS INC. (0.11%), Tower Research Capital LLC TRC (0.01%) and Meeder Asset Management Inc. (0.00%). Company insiders that own Dova Pharmaceuticals stock include Alex Sapir, David Zaccardelli, Jason Hoitt, Kevin Laliberte, Lee F Md Phd Allen, Life Sciences Maste Perceptive, Mark W Hahn, Paul B Manning, Roger Jeffs and Steven M Goldman. View Institutional Ownership Trends for Dova Pharmaceuticals.

DOVA stock was acquired by a variety of institutional investors in the last quarter, including GW&K Investment Management LLC, Gabelli Funds LLC, GABELLI & Co INVESTMENT ADVISERS INC., Tower Research Capital LLC TRC and Meeder Asset Management Inc.. Company insiders that have bought Dova Pharmaceuticals stock in the last two years include Alex Sapir, David Zaccardelli, Life Sciences Maste Perceptive, Paul B Manning and Steven M Goldman. View Insider Buying and Selling for Dova Pharmaceuticals.

Shares of DOVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of DOVA stock can currently be purchased for approximately $28.04.

Dova Pharmaceuticals has a market capitalization of $807.55 million and generates $10.35 million in revenue each year. The company earns $-72,280,000.00 in net income (profit) each year or ($2.60) on an earnings per share basis. Dova Pharmaceuticals employs 115 workers across the globe.View Additional Information About Dova Pharmaceuticals.

The official website for Dova Pharmaceuticals is http://www.dova.com/.

Dova Pharmaceuticals' mailing address is 240 Leigh Farm Road Suite 245, Durham NC, 27707. The company can be reached via phone at 919-748-5975 or via email at [email protected]